79096-54-1

Basic information

• Product Name: 1-(3-chloropropoxy)-4-nitrobenzene
• Synonyms: 1-(3-chloropropoxy)-4-nitrobenzene;UKRORGSYN-BB BBV-033260
• CAS NO: 79096-54-1
• Molecular Formula: C₉H₁₀ClNO₃
• Molecular Weight: 215.63
• Mol File: 79096-54-1.mol
• Article Data: 30

Chemical Properties

• Boiling Point: 357.514 °C at 760 mmHg
• Flash Point: 170.019 °C
• Appearance: /
• Density: 1.271 g/cm³
• CAS DataBase Reference: 1-(3-chloropropoxy)-4-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-chloropropoxy)-4-nitrobenzene(79096-54-1)
• EPA Substance Registry System: 1-(3-chloropropoxy)-4-nitrobenzene(79096-54-1)

Safety Data

• Hazardous Substances Data: 79096-54-1(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Synthesis, p. 1069, 1990 DOI: 10.1055/s-1990-27096

Upstream product

• 100-02-7 4-nitro-phenol 
• 109-70-6 1.3-chlorobromopropane 
• 107167-08-8 1-bromo-1-chloropropane 
• 88-75-5 2-hydroxynitrobenzene 
• 627-30-5 1-chloro-3-hydroxypropane 
• 28341-54-0 4-(4-nitrophenoxy)butanoic acid 
• 66971-02-6 3-(4-nitrophenoxy)-1-propanol 
• 350-46-9 4-Fluoronitrobenzene 
• 60-24-2 2-hydroxyethanethiol 

Downstream Products

• 111626-61-0 α,α-bis(4-fluorophenyl)-1-[3-(4-nitrophenoxy)propyl]-4-piperidinemethanol 
• 137898-53-4 N-<3-(4-nitrophenoxy)propyl>cyclopentylamine 
• 25836-98-0 N-(4-Methoxy-phenyl)-3-(4-nitro-phenoxy)-propylamin 
• 25836-90-2 N-<ω-(p-Nitrophenoxypropyl)>anilin 
• 128988-69-2 2-[3-(4-nitro-phenoxy)-propylsulfanyl]-ethanol 
• 92374-75-9 1-[3-(4-nitro-phenoxy)-propyl]-piperidine 
• 251552-34-8 4-(3-piperidin-1-ylpropoxy)phenylamine 
• 62424-88-8 N,N-dimethyl-3-(4-aminophenoxy)propylamine 
• 791629-14-6 1-[3-(4-nitro-phenoxy)-propyl]-1H-[1,2,3]triazole 
• 93429-13-1 4-(3-(4-nitrophenoxy)propyl)morpholine 
• 925921-03-5 C₁₅H₂₂N₂O₄ 
• 928256-57-9 4-(3-chloropropoxy)aniline 
• 91430-80-7 N, N-dimethyl-3-(4-nitrophenoxy) propan-1-amine 
• 88138-61-8 1-[3-(4-nitrophenoxy)propyl]-1H-Imidazole 

Relevant articles and documents

Design and synthesis of new carbamates as inhibitors for fatty acid amide hydrolase and cholinesterases: Molecular dynamic, in vitro and in vivo studies

As anandamide (N-arachidonoylethanolamine, AEA) shows neuroprotective effects, the inhibition of its degradative enzyme, fatty acid amide hydrolase (FAAH) has been considered as a hopeful avenue for the treatment of neurodegenerative diseases, like Alzhei

Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a serious and fatal lung disease, with a median survival of only 3–5 years from diagnosis. Janus kinase 3 (JAK3) has a well-established role in the pathogenesis of various autoimmune diseases, including rheumatoid arthritis (RA) and autoimmune-related pulmonary fibrosis. In this study, through the use of a conformationally-constrained design strategy, a series of thieno[3,2-d]pyrimidines were synthesized as potent JAK3 inhibitors for the treatment of IPF. Among them, the most potent JAK3 inhibitor, namely 8e (IC50 = 1.38 nM), significantly reduced the degree of airsacculitis and fibrosis according to hematoxylin-eosin (HE) staining assay for the lung tissue in the bleomycin (BLM)-induced pulmonary fibrosis mouse model. The clear reduction of the lung collagen deposition by the determination of Masson and hydroxyproline (HYP) content also demonstrated its efficacy in the treatment of fibrosis. In addition, 8e also reduced the expression of the inflammatory markers IL-6, IL-17A, TNF-α and malondialdehyde (MDA) in lung tissue, which indicated its higher anti-inflammatory activity compared with that of the reference agents (nintedanib and gefitinib). Furthermore, it possessed low cytotoxicity against normal human bronchial epithelia (HBE) cells (IC50 > 39.0 μM) and C57BL mice. All these evaluated biological properties suggest that 8e may be a potential JAK3 inhibitor for the treatment of IPF.

Dithiocarbamate type compound used as BTK (Bruton Tyrosine Kinase) inhibitor

The invention aims at providing a dithiocarbamate type compound used as a BTK (Bruton Tyrosine Kinase) inhibitor and a pharmaceutical composition thereof, a preparation method and application. The compound provided by the invention has a structure shown as a general formula (I). The formula (I) is shown in the description.